Chondrodysplasia Punctata, Tibial-metacarpal Type

1. Disease Information

1.1 Concise overview (current understanding)

CDP‑TM (OMIM 118651) is a very rare skeletal dysplasia within the non‑rhizomelic CDP spectrum, characterized by punctate (stippled) calcifications in cartilage/epiphyses in fetal/neonatal life and a distinctive pattern of limb shortening, especially short tibiae and short metacarpals (notably 3rd/4th), with variable vertebral anomalies. Many punctate calcifications fade/disappear in early childhood, but disproportionate short stature and orthopedic/spinal complications can persist or emerge later. (rittler1990chondrodysplasiapunctatatibiametacarpal pages 3-5, savarirayan2004longtermfollow‐upin pages 1-2, savarirayan2004longtermfollow‐upin pages 5-8)

Primary evidence (human clinical): original series (7 patients) (Rittler 1990), long-term adult follow-up (3 unrelated patients) (Savarirayan 2004), and multiple case reports including prenatal detection (Jansen 2000; Wester 2002; Kaissi 2008; Shukla 2015) (rittler1990chondrodysplasiapunctatatibiametacarpal pages 3-5, savarirayan2004longtermfollow‐upin pages 1-2, jansen2000chondrodysplasiapunctatatibialmetacarpal pages 1-4, wester2002chondrodysplasiapunctata(cdp) pages 2-3, kaissi2008progressivejointlimitations pages 2-5, shukla2015chondrodysplasiapunctatatibia pages 1-2).

1.2 Key identifiers and synonyms

A structured summary of identifiers/synonyms supported by retrieved sources is provided here:

Table: This table summarizes the disease identifiers and naming variants directly supported by the retrieved literature for chondrodysplasia punctata, tibia-metacarpal type. It is useful for harmonizing nomenclature across case reports, reviews, and database-oriented knowledge base entries.

Not found in retrieved sources: MONDO, Orphanet, ICD‑10/ICD‑11, and MeSH identifiers for this specific subtype were not present in the retrieved texts, so they cannot be asserted from this evidence set (artifact-00).

1.3 Data provenance

The CDP‑TM evidence base in this corpus is primarily individual patient reports and small case series, plus broader CDP reviews/surgical series extrapolated to CDP‑TM. (rittler1990chondrodysplasiapunctatatibiametacarpal pages 3-5, savarirayan2004longtermfollow‐upin pages 1-2, morota2017surgicalmanagementof pages 1-2)

2. Etiology

2.1 Disease causal factors

CDP‑TM etiology remains unknown. A fetal CDP‑TM report states: “the genetic defect in CP‑MT remains to be delineated.” (jansen2000chondrodysplasiapunctatatibialmetacarpal pages 4-4)

In three unrelated CDP‑TM patients followed long term, extensive investigations were unrevealing, including normal karyotypes, no SHOX deletion by FISH, normal sterol and VLCFA profiles, and no detected arylsulfatase D/E mutations, leading to the conclusion that “the etiology of CDP‑TM therefore remains unknown.” (savarirayan2004longtermfollow‐upin pages 5-8)

2.2 Risk factors

Genetic risk factors (causal variants): none have been established for CDP‑TM in the retrieved primary literature; no pathogenic variant spectrum can be listed for CDP‑TM itself. (jansen2000chondrodysplasiapunctatatibialmetacarpal pages 4-4, savarirayan2004longtermfollow‐upin pages 5-8)

Inheritance pattern (reported): CDP‑TM is usually described as sporadic with historical suggestion of autosomal dominant inheritance/new dominant mutations; Savarirayan notes it is “thought to be inherited as an autosomal dominant trait” but also that “no cases of familial recurrence have been reported” in their context. (savarirayan2004longtermfollow‐upin pages 1-2) Shukla similarly describes sporadic occurrence with “probable autosomal dominant” inheritance but cites a sibling recurrence report raising recessive inheritance or gonadal mosaicism. (shukla2015chondrodysplasiapunctatatibia pages 1-2)

Environmental/teratogenic phenocopies and exposures (important differential): CDP in general can arise from maternal exposures/conditions including warfarin, hydantoin/phenytoin, maternal vitamin K deficiency/malabsorption, and maternal autoimmune disease (e.g., SLE). (wessels2003fetuswithan pages 1-2, irving2008chondrodysplasiapunctataa pages 2-3, wessels2003fetuswithan pages 7-8)

A specific relevant observation is a case with CDP‑TM-like features in the context of maternal phenytoin treatment during pregnancy, supporting that anticonvulsant exposure can mimic or contribute to a tibia–metacarpal phenotype in some cases. (wester2002chondrodysplasiapunctata(cdp) pages 2-3)

2.3 Protective factors

No protective genetic or environmental factors for CDP‑TM were identified in the retrieved evidence.

2.4 Gene–environment interactions

Direct gene–environment interaction studies for CDP‑TM were not found in the retrieved literature. For CDP more broadly, multiple genetic etiologies and multiple maternal exposures converge on a shared endpoint of abnormal endochondral mineralization/stippling (see mechanism). (wessels2003fetuswithan pages 1-2, irving2008chondrodysplasiapunctataa pages 10-11)

3. Phenotypes

3.1 Phenotype spectrum (with onset, progression, and frequency where available)

A structured phenotype/HPO suggestion table is provided here:

Table: This table summarizes the phenotype and radiologic spectrum of chondrodysplasia punctata, tibia-metacarpal type (OMIM 118651), including onset, natural history, complications, and suggested HPO mappings based only on the specified literature.

Key recurring clinical/radiologic features include: - Stippled epiphyses / punctate calcifications (neonatal/infant; often sacral/carpal/tarsal prominent) (savarirayan2004longtermfollow‐upin pages 1-2, rittler1990chondrodysplasiapunctatatibiametacarpal pages 3-5) - Short tibiae (often bowed) with relative fibular overgrowth/“overshooting” fibula (savarirayan2004longtermfollow‐upin pages 5-8, shukla2015chondrodysplasiapunctatatibia pages 2-4) - Short metacarpals (classically 3rd/4th) and brachyphalangy (rittler1990chondrodysplasiapunctatatibiametacarpal pages 3-5, savarirayan2004longtermfollow‐upin pages 5-8) - Vertebral ossification anomalies (coronal clefts, deficient ossification; variable platyspondyly in severe infant report) (rittler1990chondrodysplasiapunctatatibiametacarpal pages 3-5, shukla2015chondrodysplasiapunctatatibia pages 2-4) - Craniofacial: midface hypoplasia/depressed nasal bridge/micrognathia (rittler1990chondrodysplasiapunctatatibiametacarpal pages 3-5, wester2002chondrodysplasiapunctata(cdp) pages 2-3) - Orthopedic complications: recurrent patellar dislocation (noted in all three long‑term adults), hip dysplasia, joint limitation/contractures, spinal stenosis (savarirayan2004longtermfollow‐upin pages 1-2, kaissi2008progressivejointlimitations pages 2-5)

Natural history (quantitative): In long-term follow-up of three unrelated CDP‑TM patients (followed 37, 25, and 32 years), adult heights were 152 cm, 138 cm, and 148 cm, with “intellectual function… normal, and physical function… well preserved,” but common morbidities included patellar dislocation (all), chronic serous otitis media (two), hip dysplasia (one), and lumbar stenosis requiring laminectomy (one). (savarirayan2004longtermfollow‐upin pages 1-2)

3.2 Quality of life impact

Formal QoL instruments (EQ‑5D/SF‑36/PROMIS) were not reported in the retrieved CDP‑TM sources. Functional impact is inferred from reported orthopedic and neurologic complications (e.g., patellar instability, joint limitation, spinal stenosis/myelopathy) and from need for surgeries/rehabilitation. (savarirayan2004longtermfollow‐upin pages 1-2, patel2023cervicalcorpectomyin pages 1-2)

4. Genetic / Molecular Information

4.1 Causal genes for CDP‑TM

No causal gene has been confirmed for CDP‑TM in the retrieved literature; multiple publications explicitly state the defect is unknown. (jansen2000chondrodysplasiapunctatatibialmetacarpal pages 4-4, savarirayan2004longtermfollow‐upin pages 5-8)

4.2 Pathogenic variants (CDP‑TM)

Because no causal gene is established, no CDP‑TM pathogenic variant list (HGNC IDs, variant classes, allele frequencies) can be provided from this evidence set.

4.3 Related CDP entities with known genes/pathways (for differential)

The CDP umbrella includes subtypes with defined mechanisms/genes: - RCDP: peroxisomal dysfunction (PEX7 highlighted) (jansen2000chondrodysplasiapunctatatibialmetacarpal pages 4-4, wessels2003fetuswithan pages 7-8) - CDPX1: ARSE-related X‑linked CDP (wessels2003fetuswithan pages 2-3, irving2008chondrodysplasiapunctataa pages 10-11) - CDPX2: cholesterol biosynthesis/sterol pathway disorders (patel2023cervicalcorpectomyin pages 2-3, wessels2003fetuswithan pages 1-2)

A comparative etiologic summary table is provided:

Table: This table compares the suspected and established etiologies of tibia-metacarpal chondrodysplasia punctata with other major CDP subtypes and embryopathic mimics. It highlights where CDP-TM remains genetically unresolved and where other CDP entities have clearer molecular or teratogenic mechanisms.

4.4 Modifier genes / epigenetics / chromosomal abnormalities

No CDP‑TM-specific modifier genes or epigenetic signatures were identified in the retrieved sources. Chromosomal anomalies are discussed as part of the general CDP differential diagnosis (not as a proven cause of CDP‑TM). (irving2008chondrodysplasiapunctataa pages 2-3)

5. Environmental Information

5.1 Environmental/lifestyle/infectious agents

CDP‑TM itself has not been linked to a specific non-genetic exposure in the core CDP‑TM case series, but CDP phenocopies are well recognized: - Warfarin embryopathy and vitamin K deficiency/malabsorption embryopathy (wessels2003fetuswithan pages 2-3, wessels2003fetuswithan pages 7-8) - Hydantoin/phenytoin embryopathy (wessels2003fetuswithan pages 7-8, wester2002chondrodysplasiapunctata(cdp) pages 2-3) - Maternal autoimmune disease (SLE) embryopathy discussed as potentially anticoagulant/vitamin K–related (wessels2003fetuswithan pages 7-8, wessels2003fetuswithan pages 2-3)

No lifestyle or infectious risk factors were identified for CDP‑TM.

6. Mechanism / Pathophysiology

6.1 Current mechanistic understanding (CDP spectrum; relevance to CDP‑TM)

Across CDP entities, the proximal pathologic event is abnormal calcium deposition in cartilage during endochondral ossification, producing radiographic stippling. (irving2008chondrodysplasiapunctataa pages 10-11, patel2023cervicalcorpectomyin pages 1-2)

A key mechanistic framework for many non‑rhizomelic CDP phenotypes is vitamin K–dependent gamma‑carboxylation of Gla proteins: - “Vit K is a cofactor of vit K carboxylase (gamma-glutamylcarboxylase, GGCX)” and deficient gamma-carboxylation is stated to be “most likely… responsible for the skeletal and cartilaginous abnormalities in CDP.” (wessels2003fetuswithan pages 3-7) - “matrix GLA protein (MGP) and bone GLA protein (BGP, osteocalcin)” are described as inhibitors of cartilage calcification/bone formation; impaired carboxylation plausibly removes this inhibition and permits ectopic calcification. (wessels2003fetuswithan pages 3-7) - Warfarin is described as inhibiting “EPHX1 and ARSE,” and hydantoin toxicity is proposed to act through EPHX1, linking maternal exposures to the same pathway. (wessels2003fetuswithan pages 7-8)

Other causal routes (CDP spectrum) include: - Peroxisomal dysfunction (PEX7) affecting cartilage development (rhizomelic CDP) (wessels2003fetuswithan pages 7-8, jansen2000chondrodysplasiapunctatatibialmetacarpal pages 4-4) - Cholesterol biosynthesis defects (CDPX2 and related entities) (patel2023cervicalcorpectomyin pages 2-3, irving2008chondrodysplasiapunctataa pages 8-10) - ARSE-related cartilage sulfate metabolism, described as an “error of cartilage metabolism in sulfate transport.” (jansen2000chondrodysplasiapunctatatibialmetacarpal pages 4-4)

CDP‑TM-specific mechanism: remains unknown, but CDP‑TM lies within the non‑rhizomelic CDP spectrum where vitamin K–related phenocopies are emphasized, and CDP‑TM has been repeatedly framed as an “unknown etiology” subtype. (savarirayan2004longtermfollow‐upin pages 5-8, irving2008chondrodysplasiapunctataa pages 10-11)

6.2 Causal chain (proposed, evidence-constrained)

A plausible, evidence-constrained chain consistent with the literature is: 1) Upstream perturbation in vitamin K cycle / gamma-carboxylation (genetic defects in GGCX/VKORC1/MGP or maternal warfarin/hydantoin; or ARSE-related pathway for CDPX1) 2) Impaired post-translational modification of mineralization regulators (e.g., MGP/osteocalcin) 3) Loss of inhibition/altered regulation of cartilage mineralization 4) Premature/ectopic cartilage calcification during endochondral ossification 5) Radiographic stippling + dysregulated growth plate architecture → limb shortening and skeletal dysplasia patterns (including tibia–metacarpal patterns) (wessels2003fetuswithan pages 3-7, chitayat2008chondrodysplasiapunctataassociated pages 11-12)

6.3 Suggested ontology terms (mechanism)

GO Biological Process (suggested): endochondral ossification; cartilage development; extracellular matrix organization; biomineral tissue development; regulation of calcification.

Cell types (CL suggested): chondrocyte; hypertrophic chondrocyte; osteoblast.

Anatomy (UBERON suggested): growth plate cartilage; tibia; fibula; metacarpal bone; vertebral column; epiphysis.

(These are ontology suggestions based on the described pathology and imaging distribution; the retrieved sources do not provide explicit ontology mappings.) (wessels2003fetuswithan pages 3-7, chitayat2008chondrodysplasiapunctataassociated pages 11-12)

6.4 Molecular profiling, models, and functional studies

No CDP‑TM-specific transcriptomic/proteomic/metabolomic signatures or model organism studies were identified in the retrieved sources.

7. Anatomical Structures Affected

Primary: long bones of the lower limb (tibia ± fibula), hands (metacarpals/phalanges), vertebrae, and epiphyseal cartilage (sites of stippling). (rittler1990chondrodysplasiapunctatatibiametacarpal pages 3-5, savarirayan2004longtermfollow‐upin pages 5-8)

Secondary/complications: knees (patellar instability), hips (dysplasia), and spine (cervical/lumbar stenosis with potential cord compression/myelomalacia). (savarirayan2004longtermfollow‐upin pages 1-2, patel2023cervicalcorpectomyin pages 1-2)

8. Temporal Development

• Onset: typically prenatal/congenital, detectable on prenatal ultrasound in some cases and on neonatal radiographs. (jansen2000chondrodysplasiapunctatatibialmetacarpal pages 1-4, wessels2003fetuswithan pages 2-3)
• Progression/course: early stippling and some vertebral clefting often resolve in infancy/early childhood, but orthopedic issues (joint limitation, patellar dislocation) and spinal stenosis/myelopathy may emerge later. (wester2002chondrodysplasiapunctata(cdp) pages 2-3, savarirayan2004longtermfollow‐upin pages 5-8, patel2023cervicalcorpectomyin pages 1-2)

9. Inheritance and Population

9.1 Epidemiology

No population prevalence/incidence estimates for CDP‑TM specifically were found in the retrieved sources.

However, available quantitative context includes: - CDP‑TM has been “described in at least 11 children” (case-based count). (savarirayan2004longtermfollow‐upin pages 1-2) - For other CDP subtypes (context): CDPX1 estimated prevalence 1 in 500,000 (one report) and RCDP incidence ~1 in 100,000. (morota2017surgicalmanagementof pages 6-8)

9.2 Inheritance pattern

CDP‑TM is generally described as sporadic with historical suggestion of autosomal dominant inheritance/new mutations, but familial recurrence has been rare/uncertain in the literature cited here. (shukla2015chondrodysplasiapunctatatibia pages 1-2, savarirayan2004longtermfollow‐upin pages 1-2)

No robust data on penetrance, expressivity, sex ratio, founder effects, or carrier frequency were found for CDP‑TM.

10. Diagnostics

10.1 Clinical and imaging diagnosis

Diagnosis relies on pattern recognition combining: - Prenatal ultrasound findings when present (limb shortening, facial hypoplasia, clubfeet, stippling) (jansen2000chondrodysplasiapunctatatibialmetacarpal pages 1-4) - Early postnatal skeletal survey demonstrating stippled epiphyses and the tibia/metacarpal pattern (savarirayan2004longtermfollow‐upin pages 1-2, rittler1990chondrodysplasiapunctatatibiametacarpal pages 3-5)

A key clinical lesson is that early radiographs are crucial because stippling can fade, making later retrospective diagnosis difficult. (kaissi2008progressivejointlimitations pages 5-5)

10.2 Biochemical and genetic testing strategy

A practical approach is to: 1) Exclude RCDP/peroxisomal disease (plasmalogens, VLCFA, phytanic acid; fibroblast studies when needed) (jansen2000chondrodysplasiapunctatatibialmetacarpal pages 1-4, irving2008chondrodysplasiapunctataa pages 3-4) 2) Exclude cholesterol pathway disorders (sterol profile; gene testing in the appropriate phenotype) (irving2008chondrodysplasiapunctataa pages 2-3) 3) Consider vitamin K pathway/coagulation studies and maternal exposure history (warfarin/hydantoin/phenytoin; malabsorption) (irving2008chondrodysplasiapunctataa pages 2-3, wessels2003fetuswithan pages 7-8) 4) Use NGS panel/exome/genome for skeletal dysplasia differential diagnosis, acknowledging that CDP‑TM may remain unsolved genetically (unger2023nosologyofgenetic pages 6-8, savarirayan2004longtermfollow‐upin pages 5-8)

10.3 Differential diagnosis

Major differentials include RCDP, CDPX1, CDPX2, Keutel syndrome, Binder phenotype, warfarin/hydantoin embryopathy, maternal vitamin K deficiency, maternal autoimmune embryopathy, chromosomal anomalies, and selected storage/metabolic disorders. (wessels2003fetuswithan pages 2-3, irving2008chondrodysplasiapunctataa pages 2-3, mirzaa1993chondrodysplasiapunctata2a pages 9-10)

11. Outcome / Prognosis

11.1 CDP‑TM prognosis

Best available direct evidence is long-term follow-up of three unrelated adults: - Follow-up durations: 37, 25, and 32 years (savarirayan2004longtermfollow‐upin pages 1-2) - Adult heights: 152, 138, and 148 cm (savarirayan2004longtermfollow‐upin pages 1-2) - Development/function: “intellectual function was normal, and physical function was well preserved.” (savarirayan2004longtermfollow‐upin pages 1-2) - Morbidities: recurrent patellar dislocation (all), chronic otitis media (two), hip dysplasia (one), lumbar stenosis requiring laminectomy (one). (savarirayan2004longtermfollow‐upin pages 1-2)

11.2 Spinal/cervical prognosis and risk

CDP broadly is reported to have cervical spine abnormalities in ~20%–38% of patients (not CDP‑TM-specific). (patel2023cervicalcorpectomyin pages 1-2)

A 2023 CDP‑TM case demonstrates that cervical disease can be clinically significant in CDP‑TM: an 18‑year‑old with CDP‑TM had dysplastic C4–C5 with kyphosis/retropulsion, cord compression, and myelomalacia, treated with C4–C5 vertebrectomies and C3–C6 anterior fusion with symptom resolution. (patel2023cervicalcorpectomyin pages 1-2, patel2023cervicalcorpectomyin media d3641eed)

12. Treatment

No disease-modifying pharmacotherapy specific to CDP‑TM was identified in the retrieved literature; management is supportive and complication-directed.

12.1 Orthopedic and rehabilitative care

Supportive measures described include physical therapy and hydrotherapy to maintain hip range of motion and function, and advice such as restricting weight-bearing/sports in certain contexts. (kaissi2008progressivejointlimitations pages 2-5)

MAXO suggestions (non-exhaustive): physical therapy; orthopedic surgery; spinal decompression; spinal fusion; assistive orthoses.

12.2 Neurosurgical management (real-world implementation)

2017 surgical series (mixed CDP subtypes including 1 CDP‑TM): among 9 infants/toddlers undergoing cervical surgery (12 operations), approaches included C1 laminectomy, occipitocervical fusion (OCF) ± halo fixation; early intervention was feasible but outcomes depended strongly on preoperative respiratory status. The authors conclude surgical decompression/fusion “generally saves lives and increases the likelihood of motor function recovery.” (morota2017surgicalmanagementof pages 1-2)

2023 case-based expert synthesis: no consensus guidelines exist; many authors recommend initial conservative management given operative risks, but surgery is indicated when symptoms correlate with stenosis/instability or when MRI shows new pathological signal; recommended approach depends on CVJ vs subaxial lesion and presence of dysplastic vertebral body. (patel2023cervicalcorpectomyin pages 3-4, patel2023cervicalcorpectomyin pages 4-5)

An imaging example from the 2023 CDP‑TM cervical myelopathy case is available (MRI progression and CT showing dysplastic C4/C5): (patel2023cervicalcorpectomyin media d3641eed).

A structured management summary is provided here:

Table: This table summarizes practical diagnostic, monitoring, orthopedic, neurosurgical, and counseling considerations for chondrodysplasia punctata, with emphasis on the tibia-metacarpal subtype. It is useful as a concise implementation-oriented guide because direct CDP-TM-specific management literature is sparse and often extrapolated from broader CDP experience.

13. Prevention

Primary prevention for genetic CDP‑TM is not established because the causal gene is unknown. Prevention considerations apply mainly to phenocopies: - Avoid warfarin exposure in pregnancy when possible; review maternal medication and vitamin K status (general CDP differential context). (wessels2003fetuswithan pages 2-3, irving2008chondrodysplasiapunctataa pages 2-3) - Manage maternal conditions associated with fetal vitamin K deficiency/malabsorption and consider teratogen counseling. (wessels2003fetuswithan pages 7-8)

Prenatal detection via ultrasound and targeted biochemical/genetic evaluation is a form of secondary prevention (early identification and counseling), especially when a prior affected pregnancy/child exists. (wessels2003fetuswithan pages 2-3, jansen2000chondrodysplasiapunctatatibialmetacarpal pages 1-4)

14. Other Species / Natural Disease

No naturally occurring CDP‑TM analogs in other species were identified in the retrieved sources.

15. Model Organisms

No CDP‑TM-specific model organism or cellular model evidence was identified in the retrieved sources.

2023–2024 developments and latest research (prioritized)

1) Cervical spine management in CDP‑TM (2023): A CDP‑TM adolescent with progressive cervical kyphosis and myelomalacia underwent anterior corpectomy/fusion with symptom resolution, and the authors emphasize CDP cervical abnormalities (20–38%) and lack of consensus guidelines, advocating individualized management and long-term follow-up. (Patel et al., published Nov 20, 2023; https://doi.org/10.3171/CASE23302) (patel2023cervicalcorpectomyin pages 1-2, patel2023cervicalcorpectomyin pages 4-5)

2) Skeletal dysplasia nosology and NGS-era diagnostics (2023): The 2023 Nosology revision reports expansion from 461 to 771 disorders and 437 to 552 genes, and highlights clinical utility for targeted panels and exome/genome interpretation (reverse phenotyping), which is relevant for unsolved entities like CDP‑TM. (Unger et al., Feb 2023; https://doi.org/10.1002/ajmg.a.63132) (unger2023nosologyofgenetic pages 6-8)

3) 2024 CDP multidisciplinary care and NGS in related subtype CDPX2: A 2024 case report of Conradi–Hünermann–Happle syndrome (CDPX2) illustrates real-world implementation of WES/NGS skeletal dysplasia panels and multidisciplinary management; while not CDP‑TM, it exemplifies current practice trends applicable to CDP differential diagnosis workups. ()

(Direct 2023–2024 molecular discovery papers specifically resolving CDP‑TM were not identified in the retrieved evidence.)

Key statistics and data extracted from recent/seminal studies

• CDP‑TM adult heights in long-term follow-up (n=3): 152, 138, 148 cm; follow-up 37, 25, 32 years (savarirayan2004longtermfollow‐upin pages 1-2).
• CDP cervical spine abnormalities (CDP overall): ~20%–38% (patel2023cervicalcorpectomyin pages 1-2).
• CDPX1 prevalence estimate (context): ~1 in 500,000; RCDP incidence (context): ~1 in 100,000 (morota2017surgicalmanagementof pages 6-8).
• Prenatal CDPX1 case series (context, not CDP‑TM): nasal hypoplasia 55%, stippling 41%, polyhydramnios 32%, shortened long bones 23% (broerenUnknownyearstoer pages 3-3).

Expert opinions / authoritative synthesis (evidence-linked)

• CDP is explicitly described as “genetically heterogeneous” and characterized by “aberrant deposition of calcium (stippled epiphyses)” in endochondral bone formation, supporting a unifying pathophysiologic endpoint despite diverse upstream causes. (morota2017surgicalmanagementof pages 1-2)
• Vitamin K–dependent gamma-carboxylation of Gla proteins is presented as a mechanistic explanation for multiple non-rhizomelic CDP entities and phenocopies; Wessels explicitly states deficient gamma-carboxylation is “most likely” responsible for skeletal/cartilaginous abnormalities in CDP. (wessels2003fetuswithan pages 3-7)

Figure evidence (cervical spine disease in CDP‑TM)

The 2023 CDP‑TM cervical myelopathy case includes MRI/CT evidence of progressive kyphosis and spinal cord myelomalacia with dysplastic C4–C5 vertebrae (Figure 1). (patel2023cervicalcorpectomyin media d3641eed)

Limitations and evidence gaps

• No MONDO/Orphanet/ICD/MeSH identifiers for CDP‑TM were present in retrieved full texts; database lookups were not available within this tool-only evidence set.
• No confirmed causal gene/variant spectrum exists in these retrieved sources for CDP‑TM; thus ClinVar/gnomAD statistics and ACMG variant classifications cannot be provided for CDP‑TM.
• No trials and no disease-modifying therapies were identified for CDP‑TM.
• QoL metrics and population epidemiology for CDP‑TM are not available in the retrieved literature.

References

1. (patel2023cervicalcorpectomyin pages 1-2): Nirali P Patel, Mark W Youngblood, Melissa A LoPresti, and Tord D Alden. Cervical corpectomy in a pediatric patient with chondrodysplasia punctata and c5 dysplasia with spinal cord compression: illustrative case. Journal of Neurosurgery: Case Lessons, Nov 2023. URL: https://doi.org/10.3171/case23302, doi:10.3171/case23302. This article has 1 citations.

2. (unger2023nosologyofgenetic pages 4-6): Sheila Unger, Carlos R. Ferreira, Geert R. Mortier, Houda Ali, Débora R. Bertola, Alistair Calder, Daniel H. Cohn, Valerie Cormier‐Daire, Katta M. Girisha, Christine Hall, Deborah Krakow, Outi Makitie, Stefan Mundlos, Gen Nishimura, Stephen P. Robertson, Ravi Savarirayan, David Sillence, Marleen Simon, V. Reid Sutton, Matthew L. Warman, and Andrea Superti‐Furga. Nosology of genetic skeletal disorders: 2023 revision. American Journal of Medical Genetics Part A, 191:1164-1209, Feb 2023. URL: https://doi.org/10.1002/ajmg.a.63132, doi:10.1002/ajmg.a.63132. This article has 474 citations.

3. (unger2023nosologyofgenetic pages 6-8): Sheila Unger, Carlos R. Ferreira, Geert R. Mortier, Houda Ali, Débora R. Bertola, Alistair Calder, Daniel H. Cohn, Valerie Cormier‐Daire, Katta M. Girisha, Christine Hall, Deborah Krakow, Outi Makitie, Stefan Mundlos, Gen Nishimura, Stephen P. Robertson, Ravi Savarirayan, David Sillence, Marleen Simon, V. Reid Sutton, Matthew L. Warman, and Andrea Superti‐Furga. Nosology of genetic skeletal disorders: 2023 revision. American Journal of Medical Genetics Part A, 191:1164-1209, Feb 2023. URL: https://doi.org/10.1002/ajmg.a.63132, doi:10.1002/ajmg.a.63132. This article has 474 citations.

4. (rittler1990chondrodysplasiapunctatatibiametacarpal pages 3-5): M. Rittler, H. Menger, and J. W. Spranger. Chondrodysplasia punctata, tibia-metacarpal (mt) type. American journal of medical genetics, 37 2:200-8, Oct 1990. URL: https://doi.org/10.1002/ajmg.1320370208, doi:10.1002/ajmg.1320370208. This article has 44 citations.

5. (savarirayan2004longtermfollow‐upin pages 1-2): Ravi Savarirayan, Robert J. Boyle, John Masel, John G. Rogers, and Leslie J. Sheffield. Longterm follow‐up in chondrodysplasia punctata, tibia–metacarpal type, demonstrating natural history. American Journal of Medical Genetics Part A, 124A:148-157, Jan 2004. URL: https://doi.org/10.1002/ajmg.a.20383, doi:10.1002/ajmg.a.20383. This article has 20 citations.

6. (savarirayan2004longtermfollow‐upin pages 5-8): Ravi Savarirayan, Robert J. Boyle, John Masel, John G. Rogers, and Leslie J. Sheffield. Longterm follow‐up in chondrodysplasia punctata, tibia–metacarpal type, demonstrating natural history. American Journal of Medical Genetics Part A, 124A:148-157, Jan 2004. URL: https://doi.org/10.1002/ajmg.a.20383, doi:10.1002/ajmg.a.20383. This article has 20 citations.

7. (jansen2000chondrodysplasiapunctatatibialmetacarpal pages 1-4): V Jansen, K Sarafoglou, A Rebarber, A Greco, N B Genieser, and R Wallerstein. Chondrodysplasia punctata, tibial-metacarpal type in a 16 week fetus. Journal of Ultrasound in Medicine, 19:719-722, Oct 2000. URL: https://doi.org/10.7863/jum.2000.19.10.719, doi:10.7863/jum.2000.19.10.719. This article has 7 citations and is from a peer-reviewed journal.

8. (wester2002chondrodysplasiapunctata(cdp) pages 2-3): Ulrika Wester, G. Brandberg, M. Larsson, T. Lönnerholm, and G. Annéren. Chondrodysplasia punctata (cdp) with features of the tibia‐metacarpal type and maternal phenytoin treatment during pregnancy. Prenatal Diagnosis, 22:663-668, Aug 2002. URL: https://doi.org/10.1002/pd.352, doi:10.1002/pd.352. This article has 12 citations and is from a peer-reviewed journal.

9. (kaissi2008progressivejointlimitations pages 2-5): Ali Al Kaissi, Klaus Klaushofer, and Franz Grill. Progressive joint limitations as the first alarming signs in a boy with short – limbed dwarfism: a case report. Cases Journal, 1:112-112, Aug 2008. URL: https://doi.org/10.1186/1757-1626-1-112, doi:10.1186/1757-1626-1-112. This article has 2 citations.

10. (shukla2015chondrodysplasiapunctatatibia pages 1-2): Anju Shukla and Shubha R. Phadke. Chondrodysplasia punctata tibia metacarpal type: report of a 1.5 year old child with severe short stature and extensive calcific stippling. Clinical Dysmorphology, 24:118–121, Jul 2015. URL: https://doi.org/10.1097/mcd.0000000000000076, doi:10.1097/mcd.0000000000000076. This article has 4 citations and is from a peer-reviewed journal.

11. (wessels2003fetuswithan pages 2-2): Marja W. Wessels, Nicolette J. Den Hollander, Ronald R. De Krijger, Peter G.J. Nikkels, Helen Brandenburg, Raoul Hennekam, and Patrick J. Willems. Fetus with an unusual form of nonrhizomelic chondrodysplasia punctata: case report and review. American Journal of Medical Genetics Part A, 120A:97-104, Jul 2003. URL: https://doi.org/10.1002/ajmg.a.20202, doi:10.1002/ajmg.a.20202. This article has 22 citations.

12. (kaissi2008progressivejointlimitations pages 5-5): Ali Al Kaissi, Klaus Klaushofer, and Franz Grill. Progressive joint limitations as the first alarming signs in a boy with short – limbed dwarfism: a case report. Cases Journal, 1:112-112, Aug 2008. URL: https://doi.org/10.1186/1757-1626-1-112, doi:10.1186/1757-1626-1-112. This article has 2 citations.

13. (kozłowski2006retrospectivediagnosisof pages 1-4): K. Kozłowski, D. Basel, and P. Beighton. Retrospective diagnosis of chondrodysplasia punctata. Australasian radiology, 50 1:55-8, Feb 2006. URL: https://doi.org/10.1111/j.1440-1673.2005.01531.x, doi:10.1111/j.1440-1673.2005.01531.x. This article has 0 citations.

14. (wessels2003fetuswithan pages 1-2): Marja W. Wessels, Nicolette J. Den Hollander, Ronald R. De Krijger, Peter G.J. Nikkels, Helen Brandenburg, Raoul Hennekam, and Patrick J. Willems. Fetus with an unusual form of nonrhizomelic chondrodysplasia punctata: case report and review. American Journal of Medical Genetics Part A, 120A:97-104, Jul 2003. URL: https://doi.org/10.1002/ajmg.a.20202, doi:10.1002/ajmg.a.20202. This article has 22 citations.

15. (wessels2003fetuswithan pages 3-7): Marja W. Wessels, Nicolette J. Den Hollander, Ronald R. De Krijger, Peter G.J. Nikkels, Helen Brandenburg, Raoul Hennekam, and Patrick J. Willems. Fetus with an unusual form of nonrhizomelic chondrodysplasia punctata: case report and review. American Journal of Medical Genetics Part A, 120A:97-104, Jul 2003. URL: https://doi.org/10.1002/ajmg.a.20202, doi:10.1002/ajmg.a.20202. This article has 22 citations.

16. (morota2017surgicalmanagementof pages 1-2): Nobuhito Morota, Satoshi Ihara, Hideki Ogiwara, and Goichiro Tamura. Surgical management of cervical spine deformity in chondrodysplasia punctata. Journal of Neurosurgery: Pediatrics, 20:378-387, Oct 2017. URL: https://doi.org/10.3171/2017.5.peds16554, doi:10.3171/2017.5.peds16554. This article has 14 citations and is from a peer-reviewed journal.

17. (jansen2000chondrodysplasiapunctatatibialmetacarpal pages 4-4): V Jansen, K Sarafoglou, A Rebarber, A Greco, N B Genieser, and R Wallerstein. Chondrodysplasia punctata, tibial-metacarpal type in a 16 week fetus. Journal of Ultrasound in Medicine, 19:719-722, Oct 2000. URL: https://doi.org/10.7863/jum.2000.19.10.719, doi:10.7863/jum.2000.19.10.719. This article has 7 citations and is from a peer-reviewed journal.

18. (irving2008chondrodysplasiapunctataa pages 2-3): Melita D. Irving, Lyn S. Chitty, Sahar Mansour, and Christine M. Hall. Chondrodysplasia punctata: a clinical diagnostic and radiological review. Clinical Dysmorphology, 17:229-241, Oct 2008. URL: https://doi.org/10.1097/mcd.0b013e3282fdcc70, doi:10.1097/mcd.0b013e3282fdcc70. This article has 121 citations and is from a peer-reviewed journal.

19. (wessels2003fetuswithan pages 7-8): Marja W. Wessels, Nicolette J. Den Hollander, Ronald R. De Krijger, Peter G.J. Nikkels, Helen Brandenburg, Raoul Hennekam, and Patrick J. Willems. Fetus with an unusual form of nonrhizomelic chondrodysplasia punctata: case report and review. American Journal of Medical Genetics Part A, 120A:97-104, Jul 2003. URL: https://doi.org/10.1002/ajmg.a.20202, doi:10.1002/ajmg.a.20202. This article has 22 citations.

20. (irving2008chondrodysplasiapunctataa pages 10-11): Melita D. Irving, Lyn S. Chitty, Sahar Mansour, and Christine M. Hall. Chondrodysplasia punctata: a clinical diagnostic and radiological review. Clinical Dysmorphology, 17:229-241, Oct 2008. URL: https://doi.org/10.1097/mcd.0b013e3282fdcc70, doi:10.1097/mcd.0b013e3282fdcc70. This article has 121 citations and is from a peer-reviewed journal.

21. (shukla2015chondrodysplasiapunctatatibia pages 2-4): Anju Shukla and Shubha R. Phadke. Chondrodysplasia punctata tibia metacarpal type: report of a 1.5 year old child with severe short stature and extensive calcific stippling. Clinical Dysmorphology, 24:118–121, Jul 2015. URL: https://doi.org/10.1097/mcd.0000000000000076, doi:10.1097/mcd.0000000000000076. This article has 4 citations and is from a peer-reviewed journal.

22. (patel2023cervicalcorpectomyin media d3641eed): Nirali P Patel, Mark W Youngblood, Melissa A LoPresti, and Tord D Alden. Cervical corpectomy in a pediatric patient with chondrodysplasia punctata and c5 dysplasia with spinal cord compression: illustrative case. Journal of Neurosurgery: Case Lessons, Nov 2023. URL: https://doi.org/10.3171/case23302, doi:10.3171/case23302. This article has 1 citations.

23. (patel2023cervicalcorpectomyin pages 2-3): Nirali P Patel, Mark W Youngblood, Melissa A LoPresti, and Tord D Alden. Cervical corpectomy in a pediatric patient with chondrodysplasia punctata and c5 dysplasia with spinal cord compression: illustrative case. Journal of Neurosurgery: Case Lessons, Nov 2023. URL: https://doi.org/10.3171/case23302, doi:10.3171/case23302. This article has 1 citations.

24. (wessels2003fetuswithan pages 2-3): Marja W. Wessels, Nicolette J. Den Hollander, Ronald R. De Krijger, Peter G.J. Nikkels, Helen Brandenburg, Raoul Hennekam, and Patrick J. Willems. Fetus with an unusual form of nonrhizomelic chondrodysplasia punctata: case report and review. American Journal of Medical Genetics Part A, 120A:97-104, Jul 2003. URL: https://doi.org/10.1002/ajmg.a.20202, doi:10.1002/ajmg.a.20202. This article has 22 citations.

25. (morota2017surgicalmanagementof pages 6-8): Nobuhito Morota, Satoshi Ihara, Hideki Ogiwara, and Goichiro Tamura. Surgical management of cervical spine deformity in chondrodysplasia punctata. Journal of Neurosurgery: Pediatrics, 20:378-387, Oct 2017. URL: https://doi.org/10.3171/2017.5.peds16554, doi:10.3171/2017.5.peds16554. This article has 14 citations and is from a peer-reviewed journal.

26. (irving2008chondrodysplasiapunctataa pages 3-4): Melita D. Irving, Lyn S. Chitty, Sahar Mansour, and Christine M. Hall. Chondrodysplasia punctata: a clinical diagnostic and radiological review. Clinical Dysmorphology, 17:229-241, Oct 2008. URL: https://doi.org/10.1097/mcd.0b013e3282fdcc70, doi:10.1097/mcd.0b013e3282fdcc70. This article has 121 citations and is from a peer-reviewed journal.

27. (irving2008chondrodysplasiapunctataa pages 8-10): Melita D. Irving, Lyn S. Chitty, Sahar Mansour, and Christine M. Hall. Chondrodysplasia punctata: a clinical diagnostic and radiological review. Clinical Dysmorphology, 17:229-241, Oct 2008. URL: https://doi.org/10.1097/mcd.0b013e3282fdcc70, doi:10.1097/mcd.0b013e3282fdcc70. This article has 121 citations and is from a peer-reviewed journal.

28. (chitayat2008chondrodysplasiapunctataassociated pages 11-12): David Chitayat, Sarah Keating, Dina J. Zand, Teresa Costa, Elaine H. Zackai, Earl Silverman, George Tiller, Sheila Unger, Stephen Miller, John Kingdom, Ants Toi, and Cynthia J.R. Curry. Chondrodysplasia punctata associated with maternal autoimmune diseases: expanding the spectrum from systemic lupus erythematosus (sle) to mixed connective tissue disease (mctd) and scleroderma report of eight cases. American Journal of Medical Genetics Part A, 146A:3038-3053, Dec 2008. URL: https://doi.org/10.1002/ajmg.a.32554, doi:10.1002/ajmg.a.32554. This article has 44 citations.

29. (mirzaa1993chondrodysplasiapunctata2a pages 9-10): GM Mirzaa. Chondrodysplasia punctata 2, x-linked. Unknown journal, 1993.

30. (patel2023cervicalcorpectomyin pages 3-4): Nirali P Patel, Mark W Youngblood, Melissa A LoPresti, and Tord D Alden. Cervical corpectomy in a pediatric patient with chondrodysplasia punctata and c5 dysplasia with spinal cord compression: illustrative case. Journal of Neurosurgery: Case Lessons, Nov 2023. URL: https://doi.org/10.3171/case23302, doi:10.3171/case23302. This article has 1 citations.

31. (patel2023cervicalcorpectomyin pages 4-5): Nirali P Patel, Mark W Youngblood, Melissa A LoPresti, and Tord D Alden. Cervical corpectomy in a pediatric patient with chondrodysplasia punctata and c5 dysplasia with spinal cord compression: illustrative case. Journal of Neurosurgery: Case Lessons, Nov 2023. URL: https://doi.org/10.3171/case23302, doi:10.3171/case23302. This article has 1 citations.

32. (mirzaa1993chondrodysplasiapunctata2 pages 9-10): GM Mirzaa. Chondrodysplasia punctata 2, x-linked. Unknown journal, 1993.

33. (savarirayan2004longtermfollow‐upin pages 8-10): Ravi Savarirayan, Robert J. Boyle, John Masel, John G. Rogers, and Leslie J. Sheffield. Longterm follow‐up in chondrodysplasia punctata, tibia–metacarpal type, demonstrating natural history. American Journal of Medical Genetics Part A, 124A:148-157, Jan 2004. URL: https://doi.org/10.1002/ajmg.a.20383, doi:10.1002/ajmg.a.20383. This article has 20 citations.

34. (broerenUnknownyearstoer pages 3-3): E Broeren. Sto er. Unknown journal, Unknown year.